Li Sheng, Chen Xiaoli, Yang Xiaoyu, Chen Zhiyao, Xiong Jiahui, Lin Yanting, Chen Liang, Lu Shiyi, Lin Lijing, Chen Jianan, Lin Manbian, Cai Xiaoliang
Department of Internal Medicine, Fuzhou Traditional Chinese Medicine Hospital, Fuzhou, China.
Department of Nephrology, Quanzhou Hospital of Traditional Chinese Medicine, Quanzhou, China.
World J Surg Oncol. 2025 Aug 22;23(1):316. doi: 10.1186/s12957-025-03972-2.
This retrospective cohort study explores the association between the interval of nanocarbon application before surgery and the detection of postoperative lymph nodes in patients undergoing gastric cancer surgery.
This retrospective study included eligible patients diagnosed with T1-3NanyM0 gastric cancer at Fuzhou Traditional Chinese Medicine Hospital between March 1, 2020, and March 31, 2023, based on predefined inclusion criteria. Participants were grouped according to the timing of nanocarbon suspension application: either on the same day as surgery or at least 3 days prior. We compared clinicopathological characteristics between these two groups.
Our findings indicate a significant increase in the number of lymph nodes detected postoperatively in patients who received nanocarbon suspension at least 3 days before surgery compared to those who received it on the same day (26.33 ± 3.42 vs. 30.41 ± 2.16, P < 0.05). Early nanocarbon suspension application was found to be safe, with no observed adverse effects or complications.
Early application of nanocarbon suspension may enhance lymph node detection, potentially allowing for more accurate pathological staging. This approach could provide valuable guidance for subsequent comprehensive anti-tumor therapy.
本回顾性队列研究探讨了胃癌手术患者术前纳米碳应用间隔时间与术后淋巴结检测之间的关联。
本回顾性研究纳入了2020年3月1日至2023年3月31日期间在福州市中医医院根据预定义纳入标准诊断为T1-3NanyM0胃癌的符合条件的患者。参与者根据纳米碳混悬液应用时间分组：手术当天或至少术前3天。我们比较了这两组的临床病理特征。
我们的研究结果表明，与手术当天接受纳米碳混悬液的患者相比，术前至少3天接受纳米碳混悬液的患者术后检测到的淋巴结数量显著增加（26.33±3.42对30.41±2.16，P<0.05）。发现早期应用纳米碳混悬液是安全的，未观察到不良反应或并发症。
早期应用纳米碳混悬液可能会增强淋巴结检测，有可能实现更准确的病理分期。这种方法可为后续的综合抗肿瘤治疗提供有价值的指导。
